Cover Image
市場調查報告書

AIMM Therapeutics B.V.:開發中產品分析

AIMM Therapeutics B.V. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 276013
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
AIMM Therapeutics B.V.:開發中產品分析 AIMM Therapeutics B.V. - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 41 Pages
簡介

AIMM Therapeutics B.V.開發癌症和感染疾病、發炎性疾病、自體免疫疾病等人體用單株抗體。還有,進行有(包含前面各種疾病)醫療上需求的疾病的預防、診斷的研究計劃。該公司採用自家公司開發的AIMSelect技術,進行個人的B細胞的不死化、區分,有助於抗體的生產。該公司還活用AIMSelect/AIMProve技術,從人體化老鼠(有人體免疫系統的專用老鼠模型)的B細胞生產抗體。

本報告提供荷蘭的生物醫藥品企業、AIMM Therapeutics B.V.(AIMM Therapeutics)的醫藥品的研究開發的進展相關分析、該公司的產品平台結構,及臨床實驗的整體進展、主要開發中產品簡介與開發情形、該公司簡介與最新趨勢等調查。

目錄

AIMM Therapeutics B.V.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台、檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

開發中產品的概要

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

藥物簡介

  • CR-8020
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • 季節性、新型流感用血球凝集本源阻礙雙特異性單株抗體
  • 急性骨髓性白血病(AML)的單株抗體
  • 大腸癌的單株抗體
  • 巨細胞病毒感染的單株抗體
  • C型肝炎單株抗體
  • 人鼻病毒感染疾病的單株抗體
  • 黑色素瘤(黑色素瘤)的單株抗體
  • MRSA感染疾病的單株抗體
  • 胰臟癌的單株抗體
  • 難辨梭狀芽孢桿菌傳染病的單株抗體
  • Parecho感染疾病的單株抗體

開發平台分析

  • 各標靶
  • 各投藥法
  • 各分子類型
  • 各作用機制

公司所在地及子公司

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07951CDB

Summary

Global Markets Direct's, 'AIMM Therapeutics B.V. - Product Pipeline Review - 2016', provides an overview of the AIMM Therapeutics B.V.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AIMM Therapeutics B.V., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AIMM Therapeutics B.V.
  • The report provides overview of AIMM Therapeutics B.V. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AIMM Therapeutics B.V.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AIMM Therapeutics B.V.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AIMM Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AIMM Therapeutics B.V.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AIMM Therapeutics B.V.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AIMM Therapeutics B.V. Snapshot
    • AIMM Therapeutics B.V. Overview
    • Key Information
    • Key Facts
  • AIMM Therapeutics B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • AIMM Therapeutics B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AIMM Therapeutics B.V. - Pipeline Products Glance
    • AIMM Therapeutics B.V. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • AIMM Therapeutics B.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • AIMM Therapeutics B.V. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • AIMM Therapeutics B.V. - Drug Profiles
    • CR-8020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Acute Myelocytic Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Colon Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cytomegalovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Hepatitis C Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Human Rhinovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Melanoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for MRSA Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Pancreatic Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-18
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-28
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Clostridium Difficile Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Hepatitis B Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AIMM Therapeutics B.V. - Pipeline Analysis
  • AIMM Therapeutics B.V. - Pipeline Products by Target
  • AIMM Therapeutics B.V. - Pipeline Products by Route of Administration
  • AIMM Therapeutics B.V. - Pipeline Products by Molecule Type
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action
  • AIMM Therapeutics B.V. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AIMM Therapeutics B.V., Key Information
  • AIMM Therapeutics B.V., Key Facts
  • AIMM Therapeutics B.V. - Pipeline by Indication, 2016
  • AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016
  • AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Out-Licensed Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AIMM Therapeutics B.V. - Phase II, 2016
  • AIMM Therapeutics B.V. - Preclinical, 2016
  • AIMM Therapeutics B.V. - Discovery, 2016
  • AIMM Therapeutics B.V. - Unknown, 2016
  • AIMM Therapeutics B.V. - Pipeline by Target, 2016
  • AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016
  • AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016

List of Figures

  • AIMM Therapeutics B.V. - Pipeline by Top 10 Indication, 2016
  • AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016
  • AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Pipeline by Target, 2016
  • AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016
  • AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016
Back to Top